Psychiatry Clinical Reviews Treating Bipolar Depression
|
|
- Mildred Carr
- 5 years ago
- Views:
Transcription
1 Mayo School of Continuous Professional Development Psychiatry Clinical Reviews Treating Bipolar Depression Mark A. Frye, MD October 6-8, 2016 Intercontinental Chicago Magnificent Mile Chicago, IL 2015 MFMER slide-1
2 Disclosures - Mark A. Frye M.D Grant Support - AssureRx, Janssen Research & Development, Mayo Foundation, Myriad, National Institute of Alcohol Abuse and Alcoholism (NIAAA), National Institute of Mental Health (NIMH), Pfizer Consultant (Mayo) - Janssen Research & Development, LLC, Mitsubishi Tanabe Pharma Corporation, Myriad Genetics, Neuralstem Inc., Sunovion, Supernus Pharmaceuticals, Teva Pharmaceuticals CME/Travel Support - American Physician Institute, CME Outfitters Speakers Bureau - NONE Financial Interest / Stock ownership / Royalties - NONE Mayo Clinic has a financial interest in AssureRx and the technology referenced in this presentation 2015 MFMER slide-2
3 Presentation Objectives Review FDA approved treatments for bipolar depression Review new /novel treatments for bipolar depression Evaluate the role of antidepressants in bipolar disorder 2015 MFMER slide-3
4 Bipolar Depression: Best Practices FDA approved Olanzapine Fluoxetine (OFC) Quetiapine monotherapy Lurasidone mono & adjunct therapy Maximize the mood stabilizer Antidepressants FDA off-label Do they work? Are they safe? Psychotherapy Novel Treatment FDA off-label antidepressants are not indicated for treatment of bipolar depression The Old Guitarist Pablo Picasso 1903 The Blue Period 2015 MFMER slide-4
5 Epidemiology Lifetime prevalence rate 4.5 % 1% for BPI, 1.1% BPII, 2.4% subthreshold Suicide 25% attempt, 15% succeed (5% never hospitalized) Comorbid anxiety and substance use disorders Greater risk suicidality and treatment emergent mania Work days lost/ ill worker/ year BP > UP, driven by depression, not mania Subsyndromal depression Functional disability & subsequent relapse Merikangas et al, Arch Gen Psychiatry 2007., Levander et al, J Affective Disorder 2007 Frye et al., Am J Psychiatry 2003., Ostacher et al, Am J Psychiatry 2010., Gitlin et al, J Clin Psychiatry 2011, Kessler et al. Am J Psychiatry 2006., Altshuler et al, J Clin Psychiatry 2002., Frye et al, J Clin Psychiatry MFMER slide-5
6 Frye, NEJM 2011;364(1): MFMER slide-6
7 Response rates of atypical antipsychotics in BP depression Placebo Active Active * * Percent Response * 10 0 OLZ/OFC Quetiapine Aripiprazole Ziprasidone 10 mg / 7.5 mg40mg 300 and 600 mg ~17 mg ~90 mg OFC, olanzapine/fluoxetine combination. *P<0.05; P<0.001 vs placebo. Calabrese et al. Am J Psychiatry Thase et al. J Clin Psychopharmacol. Tohen et al. Arch Gen Psychiatry Thase et al. J Clin Psychopharmacol. 2008;28(1): Sachs et al., J Clin MFMER slide-7
8 Lurasidone in Bipolar I depression: PREVAIL 2 Patients % % or mg/d Lurasidone P < % Placebo Compared with placebo, lurasidone associated with statistically significant reductions in MADRS scores from baseline to week 6 (primary endpoint) 13.9% Lurasidone 7.7% Placebo 9.4% Lurasidone 2.4% Placebo Response Rates* NNT = 5 Nausea NNH = 17 Akathisia NNH = 15 *Response: 50% MADRS decrease. * Loebel et al., American Journal of Psychiatry 2014; 171: and MFMER slide-8.
9 Cariprazine vs. placebo in Bipolar I depression a Mixed-effects model for repeated measures, intent-to-treat population; p values were not adjusted for multiple comparisons. Cariprazine 0.75 mg/day compared with placebo: *p<0.05; **p<0.01; ***p< Cariprazine 1.5 mg/day compared with placebo: p<0.05; p<0.01; p< Cariprazine 3.0 mg/day compared with placebo: #p<0.05; ##p<0.01; ###p< Date of download: 09/12/2016 Durgam et al., MFMER slide-9
10 Pros and cons of atypical antipsychotics in bipolar depression Pros As a class, effective in acute mania Rapid control of acute mania/mixed, rapid cycling, psychosis/no psychosis Sustained improvement of symptoms Cons Tardive dyskinesia, neuroleptic malignant syndrome Weight gain TD = tardive dyskinesia; EPS = extrapyramidal symptoms 2015 MFMER slide-10
11 Metaanalysis Lamotrigine in Acute BP Depression Study SCAB2001 SCAA2010 SCA40910 SCA30924 SCA10022 LAMLIT Overall (95% CI) Risk Ratio Favors Placebo Favors Drug Risk Ratio (95% CI) 1.71 (1.08,2.69) 1.11 (0.83,1.48) 1.09 (0.81,1.48) 1.24 (0.91,1.70) 1.26 (0.95,1.67) 1.63 (1.05,2.53) 1.26 (1.10,1.44) Weight (%) Geddes JR. British Journal Psychiatry 2009 Van der Loos ML, et al. J Clin Psychiatry MFMER slide-11
12 Metaanalysis Divalproex in Acute BP Depression 100 * P < 0.05 DVPX Serum Level µg/ml 54 µg/ml 0 DVPX (n = 17) Relative risk of remission in patients treated with divalproex versus placebo Muzine et al., J Clin Psychiatry 2011, Davis J Affect Disord 2005, Ghaemi J Clin Psychiatry MFMER slide-12
13 Pros and cons of antiepileptics (divalproex, carbamazepine) in bipolar depression Pros Effective in manic and mixed episodes Effective in alcohol withdrawal & relapse prevention Several effective in migraine prevention Cons Ineffective in acute mania (LTG, TPX, GBP) P450 3A/4 heteroinduction Weight gain & endocrine disturbances (VAL) Teratogenicity (VAL, CBZ) Rash risk CBZ = carbamazepine; VAL = valproate; LTG = lamotrigine; GBP = gabapentin; OLZ = olanzapine. DVPX = divalproex; TPX = topiramate Novick et al: 2009; Goodwin et al: 2010; Frye et al: 2006; Harden et al: 2009; Goodwin et al: 2009, Jiang et al: MFMER slide-13
14 Maximize the mood stabilizer: lithium and BP depression Mean Change in HAM-D Score n=19 n=19 n=14 Li + PAR n = 33 Li + < 0.8 meq/l Li=lithium, IMI=impramine, PAR=paroxetine n=17 Li + IMI n = 36 Li meq/l p < 0.05 * n=22 n=21 Li Only n = 43 Nemeroff et al., 2004 AM J Psychiatry 2015 MFMER slide-14
15 TSH associated with depressive relapse in lithium-maintained bipolar patients Mean TSH (µiu/ml) * 4.4 ± ± 0.4 (N = 40) (N = 13) No Drop out Drop Out For Depression Lithium Maintenance Frye et al., Acta Psychiatrica 2009; 120: MFMER slide MFMER slide-15
16 Antidepressants not effective for bipolar depression Meta-analysis 16 studies acute AD Rx vs. placebo or active comparator in BPI / II depressed patients (n=3113) The pooled treatment estimates Clinical response (RR=1.17, 95% CI, ; p=0.28) Clinical remission (RR=1.14, 95% CI, ; p=0.28) Pooled treatment estimates for 1000 patients No increase risk of switch In smaller analysis 43% TCA, 15% venlafaxine, 7% SSRI, 5% bupropion Sidor and MacQueen Journal Clnical Psychiatry 2011 and MFMER slide-16
17 Depressive episode relapse with antidepressant discontinuation 1.0 % Subjects without Relapse >12 months AD 6-12 months AD <6 months AD Number of Weeks Until Relapse Cox regression analyses log rank = 10.09, P = Altshuler L et al. Am J Psychiatry. 2003;160(7): MFMER slide-17
18 Risk Factors for Switch Mixed Depression Tricyclic antidepressants (TCA) vs Venlafaxine History of antidepressant-induced mania (AIM) Absence of Antimanic Mood Stabilizer First 3 months associated with greatest liability Low thyroid stimulating hormone (with TCAs) Polymorphism (s/s or s/l) at 5-HTTLPR Hyperthymic temperament Comorbid alcoholism Female gender and comorbid anxiety disorder Age (peripubertal > adolescents) BP I > BP II Viktorin et al., 2014 Am J Psychiatry Frye et al., 2009 Am J Psychiatry 2015 MFMER slide-18
19 Baseline mixed depression associated with treatment emergent mania (TEM) Prior to Antidepressant Treatment 3 YMRS items significantly higher in TEM motor-energy speech thought content Factor analysis to identify clusters of YMRS items that covaried and analysis of variance only identified motor/verbal activation (F(2,169)=3.99, p=.02) YMRS = Young Mania Rating Scale TEM= Treatment Emergent Mania Frye et al, Am J Psychiatry MFMER slide-19
20 DSM5 mixed features specifier BP-IV Hyperthymia + Depression Depressive Mixed State Hyperthymic Temperament Recurrent Unipolar Akiskal HS et al. J Affect Disord. 2000;59(Suppl 1):S5-S MFMER slide-20
21 Mayo Clinic Individualized Medicine Biobank for Bipolar Disorder (BP) SLC6A4 polymorphism; antidepressant induced mania 2011 MFMER slide MFMER slide-21
22 SLC6A4 S allele and AIM: metaanalysis results Study Cases Controls (N) (N) Mundo Rousseva Serretti Masoliver Ferreira Mayo Summary OR = 1.35 (95% CI: ) P = OR Metaanalysis marginally significant evidence of association between S allele and AIM+ (p=0.059) Frye et al 2015 J Clin Psychiatry 2015 MFMER slide-22
23 Ketamine for treatment resistant BP depression: replication Ketamine noncompetitive NMDA antagonist FDA approved as a general anesthetic 0.5 mg/kg over 40 minutes vs one infusion of saline placebo. Almost immediate reductions in depression rating scores. Zarate et al, MFMER slide-23
24 8-Week randomized double-blind adjunctive armodafinil in acute bipolar I depression P =.015 Percentage of Patients % Armodafinil 34.2% Placebo Response Rates a NNT = 9 a Response: 50% IDS-C30 decrease. 5.6% Armodafinil 3.5% Placebo AE Discontinuation NNH = % 4.4% Armodafinil Placebo 7% Weight Gain NNH = -37 Calabrese et al., J Clin Psychiatry 2014 epub ahead of print MFMER slide-24
25 (Pooled) 6-week randomized double-blind adjunctive pramipexole in acute BP Depression Percentage of Patients Response Rates NNT 3 ** 63.6% 1.7 mg/d N = 22 Pramipexole vs Placebo 49.4% 14.3% N = 21 **p = vs. PBO NNH Switch Rates -231 Pramipexole vs Placebo 15 BPI, 28 BPII on Li (N=18, 0.7 meq/l) DVPX (N = 18, 77 ug/ml) LTG (N=6) GBP (N=3) CBZ (N=2) 0.4% 9.1% 9.5% Pramipexole Placebo Pramipexole Placebo Response: 50% HDRS/MADRS decrease Goldberg JF, et al. Am J Psychiatry 2004;161:564-6; Zarate CA, et al. Biol Psychiatry 2004;56: MFMER slide-25
26 Intensive Psychotherapies Improve Bipolar Depression Cumulative Proportion Not Recovered CC CBT IPSRT FFT Time to Recovery (Days) N = 293 bipolar depressed outpatients Protocol meds + 9 mos: FFT (family-focused therapy) IPSRT (interpersonal and social rhythm therapy) CBT (cognitive behavior therapy) CC (collaborative care) Intensive psychotherapies Higher recovery rate Shorter time to recovery 1.6x more likely to be clinically well during any study month Miklowitz DJ et al. Arch Gen Psychiatry. 2007;64: MFMER slide-26
27 Maintenance of antidepressant response after group IPSRT for Bipolar Disorder * 18 * * * 15 Baseline Post (2 wk) 12-week YMRS IDS-C BDI-II * p<0.05, N=6, YMRS (Young Mania Rating Scale); IDS-C (Inventory of Depressive Symptomatology-Clinician Rated); BDI-II (Beck Depression Inventory-II) Hoberg et al., MFMER slide-27
28 Evidence base for treatment of BP Depression Quetiapine ++ Modafinil Armodafinil +/-/- Lurasidone ++ Fluoxetine + Lamotrigine + Lithium + Olanzapine + Pramipexole + Valproate + Aripiprazole Ziprasidone High dose Thyroxine + Sleep Dep / Pindolol + ECT + Clozapine? TMS / DBS? Ketamine +/+ ++ = At least 1 fully powered, randomized, placebo-controlled, double-blind, parallel-group, positive trial with moderate-to-large effect-size; + = At least 1 positive randomized, controlled trial or small placebo-controlled, double-blind, parallel-group trial or small effect size; = Controlled evidence of lack of efficacy;? = No data. Vieta E. 2009; Zarate CA. 2004; Diazgranados N. 2010; Goldberg JF. 2004; Frye MA. 2007; Calabrese JR MFMER slide-28
29 Conclusions Evidence-based options OFC, Quetiapine, Lamotrigine, Lurasidone Maximize the mood stabilizer Evidence base + Comorbidity Psychotic depression or psychotic illness AAP Weight neutrality ARI, LUR, ZIP, LTG Migraine valproate Smoking cessation bupropion (with MS) Antisuicidal or classic illness- lithium Antidepressants in BP depression Evidence base does not support monotherapy use Switch rate is not 0% 2015 MFMER slide-29
Bipolar Depression: Engaging the Patient. Mark Frye, MD Mayo Clinic Rochester, MN
Bipolar Depression: Engaging the Patient Mark Frye, MD Mayo Clinic Rochester, MN Mark Frye, MD Disclosures Research/Grants: AssureRX Health Inc.; Janssen Research & Development, LLC; Mayo Foundation for
More informationPsychiatry Clinical Reviews Mania Matters
Mayo School of Continuous Professional Development Psychiatry Clinical Reviews Mania Matters Mark A. Frye, MD October 6-8, 2016 Intercontinental Chicago Magnificent Mile Chicago, IL Disclosures- Mark A.
More informationTreatment of Bipolar disorder
8/6/215 Treatment of Bipolar disorder Pichai Ittasakul, M.D. Department of Psychiatry, Ramathibodi Hospital, Mahidol University Bipolar disorder Manic-depressive Illness. is characterized by the occurrence
More informationManagement of Bipolar Depression
Management of Bipolar Depression Haresh M. Tharwani, M.D. Associate Clinical Professor Medical Director-DRH & Duke Psychiatry Specialty Clinic of Cary, N.C. Bipolar Disorders (Manic-Depressive illness)
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Bipolar Depression: Putting the End Goal
More informationYour footnote
MANIA Your footnote Your footnote Cipriani A, Barbui C, Salanti G et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. The Lancet 2011;
More informationThe Pharmacological Management of Bipolar Disorder: An Update
Psychobiology Research Group The Pharmacological Management of Bipolar Disorder: An Update R. Hamish McAllister-Williams, MD, PhD, FRCPsych Reader in Clinical Psychopharmacology Newcastle University Hon.
More informationPDF created with pdffactory Pro trial version
با ی د ر ا ر وه روا ز ش ی دا ه ع وم ش ی ا ان Treatment Challenges in BD Major depressive episode Mixed states= 20% Rapid cycling= 18% (annually), 31.5% (lifetime) Psychiatric Comorbidity (substance abuse,
More informationImproving the Recognition and Treatment of Bipolar Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Improving the Recognition and Treatment of Bipolar Depression Learning Objectives Apply evidence-based tools that aid in differentiating
More informationChallenges in identifying and treating bipolar depression: a guide
Challenges in identifying and treating bipolar depression: a guide Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Overview Challenges in
More informationOverview Treatment-Resistant Bipolar Disorder. Management of Bipolar Disorder When First-Line Interventions Fail Practical Tips
Overview Management of Bipolar Disorder When Interventions Fail Practical Tips Terence A. Ketter, MD Professor of Psychiatry and Behavioral Sciences Stanford University School of Medicine Stanford, California
More informationClinical Guideline for the Management of Bipolar Disorder in Adults
Clinical Guideline for the Management of Bipolar Disorder in Adults Goal: To improve the quality of life of adults with bipolar disorder Identification and Treatment of Bipolar Disorder Criteria for Diagnosis:
More informationManaging Bipolar Depression and Mixed Episodes
Managing Bipolar Depression and Mixed Episodes Outline Diagnosing bipolar disorder with DSM-5 Treating mixed features of bipolar disorder Improving health outcomes in bipolar depression Role of psychosocial
More informationMultistate Outcome Analysis of Treatment MOAT
Multistate Outcome Analysis of Treatment MOAT Charles L. Bowden, M.D. Presented with Fond Memories of an Outstanding Statistician and Investigative Scientist Andy Leon Design contributors to low generalizability
More informationFlorida Best Practice Medication Guidelines Principles of Practice for Adults
http://flmedicaidbh.fmhi.usf.edu Florida Best Practice Medication Guidelines Principles of Practice for Adults 1. Goal of the Guidelines Persistent gaps exist in the quality of mental health care delivered
More informationAntipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationKelly Godecke, MD Department of Psychiatry University of Utah
Kelly Godecke, MD Department of Psychiatry University of Utah Epidemiology and Impact -module 2 session 1 overview of mood disorders Diagnostic Criteria of Bipolar Disorders Medications Used in Bipolar
More informationFixing the Mix-Up Over Mixed Depression
Handout for the Neuroscience Education Institute (NEI) online activity: Fixing the Mix-Up Over Mixed Depression Diagnosing and Treating DSM-5 Defined Mixed Features in Mood Disorders Learning Objectives
More informationComprehensive Pharmacologic Management of Bipolar Depression Alexander McGirr, MD, MSc 1 David J. Bond, MD, PhD 2,*
Current Treatment Options in Psychiatry (2014) 1:263 277 DOI 10.1007/s40501-014-0017-2 Mood Disorders (AH Young, Section Editor) Comprehensive Pharmacologic Management of Bipolar Depression Alexander McGirr,
More informationBipolar Depression Update 2016
Bipolar Depression Update 2016 Andrew A. Nierenberg, MD Thomas P. Hackett, MD, Endowed Chair in Psychiatry Director, Bipolar Clinic and Research Program Massachusetts General Hospital Professor of Psychiatry,
More informationBipolar Disorder A Focus on Depression
clinical practice Bipolar Disorder A Focus on Depression Mark A. Frye, M.D. This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies
More informationBipolar Disorder in Youth
Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital Pediatric-Onset
More informationWhat s new in the treatment of bipolar disorder?
What s new in the treatment of bipolar disorder? Dr. David Cousins MRC Clinician Scientist Institute of Neuroscience Newcastle University NCMD 2017 What s new in the treatment of bipolar disorder? Dr.
More informationBipolar Depression Update 2015
Bipolar Depression Update 2015 Andrew A. Nierenberg, MD Thomas P. Hackett, MD, Chair in Psychiatry Director, Bipolar Clinic and Research Program Massachusetts General Hospital Professor of Psychiatry,
More informationA systematic review of the evidence on the treatment of rapid cycling bipolar disorder
Bipolar Disorders 2013: 15: 115 137 Review Article Ó 2013 John Wiley and Sons A/S Published by Blackwell Publishing Ltd. BIPOLAR DISORDERS A systematic review of the evidence on the treatment of rapid
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More information35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child
Stephen M. Strakowski, MD Chart Review: Bipolar Disorder PATIENT INFO 35 Age: Female Sex: 35-year-old woman with Hx of BPII Dx; currently separated from husband; has 1 child Background: SI and hospitalization
More informationResubmission. Scottish Medicines Consortium
Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals
More informationThe Challenge of Treatment in Bipolar Depression: Evidence from Clinical Guidelines, Treatment Recommendations and Complex Treatment Situations
53 The Challenge of Treatment in Bipolar Depression: Evidence from Clinical Guidelines, Treatment Recommendations and Complex Treatment Situations Authors S. Köhler 1, S. Gaus 1, T. Bschor 2, 3 Affiliations
More informationSOMEWHERE OVER THE RAINBOW: RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF DEPRESSIVE MIXED STATES
SOMEWHERE OVER THE RAINBOW: RECOMMENDATIONS FOR THE DIAGNOSIS AND TREATMENT OF DEPRESSIVE MIXED STATES Learning Objectives Impart the importance of screening for the presence of mixed features and family
More informationPractice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder,
Practice Parameter for the Assessment and Treatment of Children and Adolescents with Bipolar Disorder, Journal of the Academy of Child and Adolescent Psychiatry, 1997 Primary Authors: Jon McClellan MD
More informationWhere to from Here? Evidence-Based Strategies for Treatment of Refractory Depression
Where to from Here? Evidence-Based Strategies for Treatment of Refractory Depression Michael D. Jibson, MD, PhD Professor of Psychiatry University of Michigan Major Depression #1 WHO cause of disability
More informationClinical Perspective on Conducting TRD Studies. Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark
Clinical Perspective on Conducting TRD Studies Hans Eriksson, M.D., Ph.D., M.B.A. Chief Medical Specialist, H. Lundbeck A/S Valby, Denmark Overview of Presentation Treatment-Resistant Depression (TRD)
More informationSolving Clinical Challenges in Bipolar Disorder
Overview Bipolar Disorder Solving Clinical Challenges Solving Clinical Challenges in Bipolar Disorder Terence A. Ketter, MD Professor Emeritus Department of Psychiatry and Behavioral Sciences Stanford
More informationLithium in bipolar disorders.
Lithium in bipolar disorders. S. Mehdi Samimi Ardestani M.D. Department of Psychiatry, Shahid Beheshti University of Medical Science, Behavioral science research center Iranian psychiatric association,
More informationPractical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current Clinical Guidelines
SECOND-GENERATION ANTIPSYCHOTICS IN BIPOLAR DISORDER Practical Guide to Long-Term Pharmacotherapy in Bipolar Disorder: An Updated Synthesis of Current s Flavio Guzman, MD Editor Psychopharmacology Institute
More informationBIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD
Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD PROFESSOR DEPARTMENT OF PSYCHIATRY UNIVERSITY
More informationPharmacotherapy of Bipolar Disorder Roger S. McIntyre, MD, FRCPC
Pharmacotherapy of Bipolar Disorder Roger S. McIntyre, MD, FRCPC Professor of Psychiatry and Pharmacology University of Toronto Head, Mood Disorders Psychopharmacology Unit University Health Network Toronto,
More informationObjectives. DSM-V Changes: Elimination of Multiaxial Diagnostic System
Conflicts of Interest I have no conflicts to disclose. 2014 Updates to the Updates in Pharmacotherapy Webinar Psychiatry Updates for Pharmacotherapy Specialists Jacintha S. Cauffield, Pharm.D., BCPS Associate
More informationEffectiveness of psychotropic medications in the maintenance phase of bipolar disorder: a meta-analysis of randomized controlled trials
International Journal of Neuropsychopharmacology (2011), 14, 1029 1049. f CINP 2011 doi:10.1017/s1461145711000885 Effectiveness of psychotropic medications in the maintenance phase of bipolar disorder:
More informationComparison of the Usefulness of Lithium and Valproate
Review Article CNPT4(2013) 1-5 Comparison of the Usefulness of Lithium and Valproate, M.D., Ph.D. Department of Neuropsychiatry, Oita University Faculty of Medicine ABSTRACT This review shows that lithium
More informationImproving Diagnosis and Symptoms in Patients With Bipolar Depression: Contemporary Strategies Discussion 1
Discussion 1 The following is a transcript from a Web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by an educational
More informationIt's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum
It's Cycling, Not Polarity Understanding and Diagnosing the Bipolar Spectrum Session 4022: American Psychiatric Nurses Association National Conference, Louisville, KY Andrew Penn, RN, MS, NP, CNS Psychiatric
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationDSM-5 Criteria: Bipolar Disorders
DSM-5 Criteria: Bipolar Disorders Box 1. Bipolar I Disorder: For a diagnosis of bipolar I disorder, it is necessary to meet the following criteria for a manic episode. The manic episode may have been preceded
More informationAugmentation and Combination Strategies in Antidepressants treatment of Depression
Augmentation and Combination Strategies in Antidepressants treatment of Depression Byung-Joo Ham, M.D. Department of Psychiatry Korea University College of Medicine Background The response rates reported
More informationBipolar Disorders. Disclosure Statement. I have no financial disclosures or conflicts of interest
Bipolar Disorders Ahsan Naseem, MD Diplomate American Board of Psychiatry and Neurology Adult and Geriatric Psychiatry Medical Director Bryan Heartland Psychiatry Bryan Physician Network Partner Cheney
More informationNOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression)
NOVEL INDICATIONS: Experiences from a Study in MDD with Mixed Features (Mixed Depression) 11 APRIL 2013 Josephine Cucchiaro, PhD Vice President Clinical Operations & Project Management Sunovion Pharmaceuticals
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More information#CHAIR2016. September 15 17, 2016 The Biltmore Hotel Miami, FL. Sponsored by
#CHAIR2016 September 15 17, 2016 The Biltmore Hotel Miami, FL Sponsored by Pediatric Bipolar Disorder: Diagnosis and Management Karen Dineen Wagner, MD, PhD University of Texas Medical Branch Galveston,
More information3. Depressione unipolare
3. Depressione unipolare Depressione unipolare con mancata risposta al trattamento con SSRI Question: Should switching from SSRIs to another antidepressant class vs switching within class (SSRIs) be used
More informationSeptember 26 28, 2013 Westin Tampa Harbour Island. Co-sponsored by
September 26 28, 2013 Westin Tampa Harbour Island Co-sponsored by Best Practices in the Management of Bipolar Disorder Robert M. A. Hirschfeld, MD University of Texas Medical Branch Galveston, TX Peter
More informationPsychiatry in Primary Care: What is the Role of Pharmacist?
Psychiatry in Primary Care: What is the Role of Pharmacist? Benjamin Chavez, PharmD, BCPP, BCACP Clinical Associate Professor Director of Behavioral Health Pharmacy Services January 12, 2019 Disclosure
More informationApproach to Bipolar Disorder Family Medicine Forum November 14 17, 2018 Toronto, Ontario
Approach to Bipolar Disorder Family Medicine Forum November 14 17, 2018 Toronto, Ontario Jon Davine, MD, CCFP, FRCP(C) Associate Professor, McMaster University Faculty/Presenter Disclosure Faculty: Dr.
More informationIs Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A
Is Depression management getting you down? G. Michael Allan Director Programs and Practice Support, CFPC Professor, Family Med, U of A Faculty/Presenter Disclosures Faculty: Mike Allan Salary: College
More informationBipolar disorder, sometimes called manicdepressive
XXASIN_2_4_p151_157 10/25/04 3:45 PM Page 151 ROLE OF ANTIPSYCHOTIC MEDICATIONS IN TREATING BIPOLAR DISORDER * Mary Jane Strong, APRN, MS, CS ABSTRACT Although no cure exists for bipolar disorder, treatment
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 6. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationBipolar Disorder 4/6/2014. Bipolar Disorder. Symptoms of Depression. Mania. Depression
Bipolar Disorder J. H. Atkinson, M.D. Professor of Psychiatry HIV Neurobehavioral Research Programs University of California, San Diego KETHEA, Athens Slides courtesy of John Kelsoe, M.D. Bipolar Disorder
More informationMedications for Anxiety & Behavior in Williams Syndrome. Disclosure of Potential Conflicts. None 9/22/2016. Evaluation
Medications for Anxiety & Behavior in Williams Syndrome Christopher J. McDougle, M.D. Director, Lurie Center for Autism Professor of Psychiatry and Pediatrics Massachusetts General Hospital and MassGeneral
More informationIs there consensus across international evidence-based guidelines for the management of bipolar disorder?
Acta Psychiatr Scand 2017: 135: 515 526 All rights reserved DOI: 10.1111/acps.12717 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ACTA PSYCHIATRICA SCANDINAVICA Review Is there consensus
More informationHHS Public Access Author manuscript Bipolar Disord. Author manuscript; available in PMC 2016 June 01.
A single infusion of ketamine improves depression scores in patients with anxious bipolar depression Dawn F Ionescu a,b, David A Luckenbaugh c, Mark J Niciu c, Erica M Richards c, and Carlos A Zarate Jr
More informationPennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016
Pennsylvania Academy of Family Physicians Foundation & UPMC 43rd Refresher Course in Family Medicine CME Conference March 10-13, 2016 Disclosures: Bipolare Disorder Initial Evaliaton and Referral Criteria
More informationUniversity of Groningen. Lamotrigine in bipolar depression Loos, Marcus Lambertus Maria van der
University of Groningen Lamotrigine in bipolar depression Loos, Marcus Lambertus Maria van der IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
More informationMood Disorders.
Mood Disorders Shamim Nejad, MD Medical Director, Psycho-Oncology Services Swedish Cancer Institute Swedish Medical Center Seattle, Washington Shamim.Nejad@swedish.org Disclosures Neither I nor my spouse/partner
More informationBipolar disorder is a lifelong debilitating PROCEEDINGS EVOLVING ROLE OF ANTIPSYCHOTIC THERAPY IN THE MANAGEMENT OF BIPOLAR DISORDER *
EVOLVING ROLE OF ANTIPSYCHOTIC THERAPY IN THE MANAGEMENT OF BIPOLAR DISORDER * Karen C. Tugrul, RN, BSN ABSTRACT The lifetime prevalence of bipolar I disorder in the United States is reported to be between
More informationTreating treatment resistant depression
Treating treatment resistant depression These slides are the intellectual property of Ian Anderson and must not be reproduced Ian Anderson Neuroscience and Psychiatry Unit University of Manchester and
More informationDepartment of Psychiatry & Behavioral Sciences. University of Texas Medical Branch
Depression in Childhood: Advances and Controversies in Treatment Karen Dineen Wagner, MD, PhD Marie B. Gale Centennial Professor & Vice Chair Department of Psychiatry & Behavioral Sciences Director, Division
More informationClozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders
Neuropsychobiology 2002;45(suppl 1):37 42 Clozapine as Add-On Medication in the Maintenance Treatment of Bipolar and Schizoaffective Disorders A Case Series B. Hummel S. Dittmann A. Forsthoff N. Matzner
More informationLevel of response and safety of pharmacological monotherapy in the treatment of acute bipolar I disorder phases: a systematic review and meta-analysis
International Journal of Neuropsychopharmacology (2010), 13, 813 832. Copyright f CINP 2010 doi:10.1017/s1461145709991246 REVIEW Level of response and safety of pharmacological monotherapy in the treatment
More informationMedication for Anxiety and Depression. PJ Cowen Department of Psychiatry, University of Oxford
Medication for Anxiety and Depression PJ Cowen Department of Psychiatry, University of Oxford Topics Medication for anxiety disorders Medication for first line depression treatment Medication for resistant
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 05 May 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 05 May 2010 LAMICTAL 2 mg, dispersible / chewable tablet B/30 (CIP: 354 581-7) LAMICTAL 5 mg, dispersible / chewable
More informationBipolar disorders: treatment options and patient satisfaction
REVIEW Bipolar disorders: treatment options and patient satisfaction Charles Bowden Vivek Singh Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, TX,
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 February 2009
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 February 2009 ABILIFY 5 mg tablets, pack of 28 (CIP: 364 069-7) ABILIFY 10 mg tablets, pack of 28 (CIP: 364 073-4)
More informationTrial No.: RIS-USA-102 Clinical phase: III
SYNOPSIS Trial identification and protocol summary Company: Johnson & Johnson Pharmaceutical Research and Development, a division of Janssen Pharmaceutica, N.V. Finished product: Risperdal Active ingredient:
More informationBipolar Disorder Clinical Practice Guideline Summary for Primary Care
Bipolar Disorder Clinical Practice Guideline Summary for Primary Care DIAGNOSIS AND CLINICAL ASSESSMENT Bipolar Disorder is categorized by extreme mood cycling; manifested by periods of euphoria, grandiosity,
More informationSummary ID#7029. Clinical Study Summary: Study F1D-MC-HGKQ
CT Registry ID# 7029 Page 1 Summary ID#7029 Clinical Study Summary: Study F1D-MC-HGKQ Clinical Study Report: Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated with Bipolar
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationComparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis
Acta Psychiatr Scand 2014: 130: 452 469 All rights reserved DOI: 10.1111/acps.12343 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd ACTA PSYCHIATRICA SCANDINAVICA Meta-analysis Comparative
More informationN e w s R e l e a s e
Sunovion Pharmaceuticals Inc. 84 Waterford Drive, Marlborough, MA 01752-7010 Tel 508-481-6700 N e w s R e l e a s e Contact: Patrick Gaffey Senior Director, Corporate Communications Sunovion Pharmaceuticals
More informationThe Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients with Bipolar Disorder
Zahedan Journal of Research in Medical Sciences Journal homepage: www.zjrms.ir The Comparison of the Effectiveness of Thiothixene and Risperidone as a Combination with Lithium for the Treatment of Patients
More informationBipolar Disorder Demystified. Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry
Bipolar Disorder Demystified Cerrone Cohen, MD FABPN, FABFM Duke Departments of Family Medicine and Psychiatry Underdiagnoses of Depression In Primary Care 2005 Study of 650 primary care patients on antidepressants
More informationMajor Depressive Disorder (MDD) in Children under Age 6
in Children under Age 6 Level 0 Comprehensive assessment. Refer to Principles of Practice on page 5. Level 1 Psychotherapeutic intervention (e.g., dyadic therapy) for 6 to 9 months; assessment of parent/guardian
More informationA Critical Review of. Current Guidelines for Bipolar Disorder. R. Hamish McAllister-Williams, MD, PhD, MRCPsych
A Critical Review of Psychobiology Research Group Current Guidelines for Bipolar Disorder R. Hamish McAllister-Williams, MD, PhD, MRCPsych Reader in Clinical Psychopharmacology University of Newcastle
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 2 November 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 2 November 2011 SYCREST 5 mg, sublingual tablet B/60 (CIP code: 415 241-6) B/100 (CIP code: 579 353-1) SYCREST 10
More informationMood Disorders and Addictions: A shared biology?
Mood Disorders and Addictions: A shared biology? Dr. Paul Stokes Clinical Senior Lecturer, Centre for Affective Disorders, Department of Psychological Medicine Disclosures No relevant disclosures: No paid
More informationForty-Eighth Annual Teaching Conference Pediatrics for the Practitioner -UT Health Science Center San Antonio School of Medicine June 10-12, 2011
Adelaide Robb, MD Associate Professor Psychiatry and Pediatrics Source Advisory Board Disclosure Speaker s Bureau Bristol Myers Squibb Yes Yes Yes Epocrates Research Contract Royalties Yes Stock Janssen
More informationBipolar Disorders Expert Column Series Rapid-Cycling Bipolar Disorder: Emerging Treatments and Enduring Controversies
To Print: Click your browser's PRINT button. Bipolar Disorders Expert Column Series Rapid-Cycling Bipolar Disorder: Emerging Treatments and Enduring Controversies Joseph F. Goldberg, MD; Jinger Hoop, MD
More informationMixing and Matching: Layering Medications as Family Physicians
Mixing and Matching: Layering Medications as Family Physicians Family Medicine Forum Vancouver, B.C. November 9-12, 2016. Jon Davine, CCFP, FRCP(C) McMaster University Objectives Discuss different examples
More informationDiagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical
Diagnosis and treatment of acute agitation and aggression in patients with schizophrenia and bipolar disorder: evidence for the efficacy of atypical antipsychotics 1 Abstract Acute agitation and aggression
More informationClinical Medicine Reviews in Therapeutics. Bipolar Disorder in Year Old Patients: Treatment Options and Cautions
Clinical Medicine Reviews in Therapeutics Review Bipolar Disorder in 10 17 Year Old Patients: Treatment Options and Cautions Patricia Alvaro 1 and Soledad Romero 2 1 Institute Neuropsychiatric and Addictions
More informationTreatments for Acute Bipolar Depression: Metaanalyses of Placebo-controlled, Monotherapy Trials of Anticonvulsants, Lithium and Antipsychotics
Review 43 Treatments for Acute Bipolar Depression: Metaanalyses of Placebo-controlled, Monotherapy Trials of Anticonvulsants, Lithium and Antipsychotics Authors V. Selle 1, 2, S. Schalkwijk 1, 3, G. H.
More informationPRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS. Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA
CASE #1 PRACTICAL MANAGEMENT OF DEPRESSION IN OLDER ADULTS Lee A. Jennings, MD MSHS Assistant Professor Division of Geriatrics, UCLA OBJECTIVES Epidemiology Presentation in older adults Assessment Treatment
More informationKorean Medication Algorithm Project for Bipolar Disorder 2018 (KMAP-BP 2018): Fourth Revision
Original Article https://doi.org/10.9758/cpn.2018.16.1.434 https://doi.org/10.9758/cpn.2018.16.4.434 pissn 1738-1088 / eissn 2093-4327 Clinical Psychopharmacology and Neuroscience 2018;16(4):434-448 Copyrightc
More informationLong-term Treatment in Bipolar Disorder: Fall 2015 Update
Long-term Treatment in Bipolar Disorder: Fall 2015 Update Roy H. Perlis, MD MSc Center for Experimental Drugs and Diagnostics Massachusetts General Hospital Harvard Medical School rperlis@partners.org
More informationBipolar treatment update
Bipolar treatment update Evidence is driving change Texas Medication Algorithm Project will weigh data on atypical antipsychotics in mania and on continuing antidepressants after bipolar depression remits.
More informationCNS SPECTRUMS. CME Review Article. Treatment of Bipolar Depression: Making Sensible Decisions
CNS SPECTRUMS CME Review Article Treatment of Bipolar Depression: Making Sensible Decisions This activity is sponsored by the Neuroscience Education Institute CME Information Accreditation and Credit Designation
More informationTreatment of Bipolar Disorder in Youth
Treatment of Bipolar Disorder in Youth Janet Wozniak, M.D. Associate Professor of Psychiatry Director, Pediatric Bipolar Disorder Research Program Harvard Medical School Massachusetts General Hospital
More information4/29/2016. Psychosis A final common pathway. Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue
Early Intervention in Psychotic Disorders: Necessary, Effective, and Overdue Disclosures Financial relationships with commercial interests Douglas R. Robbins, M.D. Maine Medical Center Tufts University
More informationInterventions for acute depression study characteristics. Abbreviations Australia bipolar I disorder. Great Britain
APPENDIX 16: INTERVENTIONS FOR ACUTE DEPRESSION STUDY CHARACTERISTICS 1.1 Pharmacological interventions... 2 1.2 Nutritional interventions... 7 1.3 Physical interventions... 7 Abbreviations BPI CHN Dur
More informationManaging Multiple Comorbidities in Bipolar Disorder
Available at CurrentPsychiatry.com/BipolarDepression A SUPPLEMENT TO This promotional, non-cme program is intended only for health care professionals involved in the treatment of adult patients with bipolar
More information